Brain-On-chip Modeling Service

Creative Biolabs provides custom Brain-on-Chip modeling services for neuroscience programs that need to reproduce controlled neural microenvironments, separate vascular and parenchymal exposures, measure cell-cell communication, or test candidate efficacy and neurotoxicity in a human-relevant microphysiological system. The service is suited to neurovascular-unit research, blood-brain barrier transport, neuroinflammation, neural-network function, disease modeling, and compound prioritization.

Build a Brain-On-Chip Around the Research Decision

The starting point is the decision the model must support. A permeability project needs a stable vascular barrier and controlled luminal-to-tissue exposure. A neuroinflammation study needs defined glial participation, stimulus timing, and spatially resolved inflammatory readouts. A neural-network program may instead prioritize maturation, connectivity, spontaneous activity, and pharmacological responsiveness. We therefore align biological complexity with the primary decision rather than adding cell types or sensors that do not improve interpretation.

A fit-for-purpose design can be configured to answer questions such as:

• Compartment choice: Should the system model neuronal tissue alone, a neurovascular interface, spatially separated neural populations, or a linked organ-to-brain exposure route?
• Cell relevance: Which neuronal subtype, glial population, endothelial source, donor background, disease genotype, or isogenic control is necessary for the intended claim?
• Exposure control: Does the test article enter through a vascular channel, diffuse across a barrier, follow a concentration gradient, or act directly in the neural compartment?
• Functional evidence: Which primary endpoint will determine success, and which orthogonal readouts will distinguish target activity from general cytotoxicity or barrier disruption?
• Operating window: What maturation period, flow condition, challenge intensity, dosing schedule, sampling interval, and recovery window create a stable but responsive model?
• Translation plan: Should prioritized findings be reproduced in a second donor, patient-derived line, altered architecture, 3D organoid, or complementary in vivo model?

The service can be connected to our Organ-On-Chip Modeling Services, BBB-On-Chip Modeling Service, and Brain Organoid Modeling Service when the program requires an adjacent or higher-complexity model.

Choose the Architecture That Controls Exposure and Crosstalk

Brain-on-Chip is not a single model format. The geometry determines which cells can communicate, what transport route is measured, how shear and gradients are imposed, and which readouts remain accessible. Model selection therefore balances biological fidelity, imaging access, assay robustness, sample volume, throughput, and the time required to establish a qualified culture.

Neural Tissue and Circuit Models

Neurons can be cultured as two-dimensional networks, ECM-supported 3D tissues, spheroids, organoids, or regionally patterned populations, depending on the question. Microchannels can guide axons between compartments while limiting bulk fluid exchange, enabling studies of axonal transport, network directionality, lesion response, synaptic propagation, or selective treatment of somatic and distal processes. Human iPSC-derived excitatory, inhibitory, dopaminergic, sensory, or motor neuronal populations can be combined with astrocytes, oligodendrocytes, or microglia where those cells are mechanistically relevant.

Programs requiring defined human cell backgrounds can incorporate cells generated through our iPSC-derived Neuron and NPC Generation Service or use a broader Neuron, Astrocyte and Microglia Co-culture Assay as a supporting comparison.

Neurovascular and Barrier-Coupled Models

A neurovascular chip can place endothelial cells under perfusion adjacent to pericytes, astrocytes, neurons, or a mixed neural tissue compartment. This supports measurement of apparent permeability, tracer exclusion, junction organization, transporter activity, inflammatory barrier opening, and tissue response after trans-barrier exposure. Membrane-based and membrane-free interfaces offer different advantages: membranes simplify sampling and electrical measurements, whereas direct ECM interfaces can improve physical proximity and cell-cell communication. The choice is made before assay development because geometry changes both transport and interpretation.

Barrier-focused work may use iPSC-derived BBB Model Generation, the ready-to-use Human Blood Brain Barrier Model, or a 3D Blood Brain Barrier Model Assay Kit as a benchmark or complementary format.

Disease and Injury Contexts

Disease phenotypes can be introduced through patient-derived or engineered cells, pathological proteins, inflammatory stimuli, hypoxia or nutrient stress, mechanical injury, excitotoxic challenge, or project-specific genetic perturbation. The model can be oriented toward Alzheimer's disease, Parkinson's disease, epilepsy, ischemic injury, traumatic brain injury, neurodevelopmental disorders, neuroinflammation, or other neurological questions when the chosen cell types and endpoint window support the intended conclusion. A disease chip is qualified against its own baseline and control response; the presence of multiple cell types alone is not treated as evidence of disease relevance.

Engineer the Microenvironment Before Scaling

Small changes in material, matrix, flow, and medium can alter compound availability and cellular phenotype. Feasibility work therefore establishes the engineering and biological operating window together. This reduces the risk of scaling a visually attractive culture that lacks stable function or delivers an unknown test concentration to the cells.

• Chip material and adsorption: PDMS, thermoplastics, glass, coatings, tubing, and seals differ in small-molecule binding, gas exchange, optical performance, and compatibility with long-term culture. Compound recovery or mass-balance checks can be added where adsorption is a concern.
• Extracellular matrix: Matrix identity, stiffness, concentration, lot, gelation, and channel confinement influence neurite growth, glial state, vessel formation, and diffusion. The formulation is selected for both biology and reproducible loading.
• Perfusion and gradients: Flow rate, hydrostatic pressure, shear stress, recirculation, directionality, and media exchange are matched to the vascular or neural compartment. Tracer studies can verify fluidic isolation and effective transport paths.
• Cell source and maturity: Cell identity, donor/genotype, differentiation efficiency, passage, plating density, ratio, maturation time, and batch acceptance criteria are documented before challenge or dosing.
• Medium compatibility: Co-cultures may require a shared formulation or controlled separation of incompatible media. Pilot studies assess survival and phenotype across the complete culture interval, not only after seeding.
• Imaging and sampling access: Optical thickness, field-of-view coverage, electrode position, reservoir volume, and sample-removal frequency are designed around the primary readout and analysis plan.

Qualification can include flow and leak checks, tracer transport, endothelial junction markers, lineage markers, baseline viability, morphology, spontaneous neural activity, challenge responsiveness, positive and negative controls, inter-chip variability, and predefined acceptance ranges. Model complexity is increased only after the simpler system provides a stable reference state.

Measure Function Across Compartments

• Barrier and transport: TEER where compatible, fluorescent tracer permeability, apparent permeability coefficients, tight-junction and adherens-junction imaging, transporter expression or function, luminal and tissue concentrations, and barrier recovery after challenge.
• Neural network function: Spontaneous or evoked calcium activity, multi-electrode-array firing and synchrony, stimulus-response testing, neurotransmitter release, synaptic-marker imaging, and network connectivity metrics.
• Cell health and morphology: Viability, membrane integrity, apoptosis, cell count, neurite length and branching, axonal continuity, synapse density, mitochondrial status, oxidative stress, and cell-type-specific survival.
• Glial and inflammatory response: Astrocyte and microglial morphology, activation markers, cytokines and chemokines, inflammasome-related signals, phagocytosis, and spatial association with neuronal or vascular injury.
• Disease-linked pathology: Amyloid or tau burden, alpha-synuclein handling, protein uptake or propagation, myelination, excitotoxic injury, hypoxia-response markers, or genotype-specific phenotypes selected for the disease hypothesis.
• Compound disposition and effect: Dose-response, time course, target engagement, barrier penetration, recovery, cellular exposure, efficacy, off-target stress, and neurotoxicity measured in the same system or in staged companion assays.

Functional packages can incorporate Calcium Imaging Assays, Neuronal MEA Assays, Neuronal Toxicity Assays, and Microglia Activation Assays to confirm specific findings outside the chip when useful.

Related Research

The following studies illustrate two practical design principles: a screening-ready neural chip should connect functional, morphological, and viability endpoints, while a neurovascular chip should define the route of exposure and the cellular composition of both vascular and brain compartments.

Parallel Functional and Morphological Evaluation in 3D Neural Networks

Wevers and colleagues cultured three-dimensional networks of human iPSC-derived neurons and astrocytes in a microfluidic plate format and assessed compound effects using calcium imaging, cell viability, and neurite outgrowth. GABA and tetrodotoxin reduced neuronal firing, while neurotoxic compounds produced concentration-dependent changes in viability or neurite structure. The work shows why a Brain-on-Chip screening plan benefits from combining rapid functional readouts with morphology and cell-health measures rather than interpreting any single signal in isolation.

Fig. 1 Compound effects measured by calcium activity, cell viability, and neurite outgrowth in a 3D neuronal-glial microfluidic platform.^1,3

A Perfused Neurovascular Route for Multicellular Brain Toxicity Testing

Koo, Hawkins, and Yun developed a membrane-free, two-compartment platform with a perfused endothelial channel alongside a collagen-embedded brain compartment containing neuronal, astrocytic, and microglial cells. The system was used to evaluate organophosphate penetration, acetylcholinesterase activity, cell viability, and residual compound. The study highlights the value of explicitly separating the vascular route from the tissue response and of defining cell ratios, perfusion, and barrier characteristics before interpreting downstream neural effects.

Fig. 2 Construction of a two-compartment, perfused tetra-culture Brain-on-Chip with endothelial, neuronal, astrocytic, and microglial components.^2,3

Frequently Asked Questions

1. What types of Brain-on-Chip models can Creative Biolabs develop?

   Creative Biolabs can configure perfused neural-tissue chips, neurovascular or BBB chips, compartmentalized neural-circuit devices, 3D multicellular neural chips, and plate-integrated microfluidic arrays. Architecture, cell composition, flow, matrix, and readouts are selected for the specific biological and development decision.

2. How do you select the most appropriate Brain-on-Chip architecture?

   We begin with the route of exposure, cells that must communicate, primary endpoint, imaging or sensing requirement, throughput, and acceptable model complexity. The simplest architecture that preserves the necessary mechanism is qualified first, with additional compartments or cell types added only when they improve interpretation.

3. Can the model use human iPSC-derived neural and vascular cells?

   Yes. Depending on feasibility and project goals, models can incorporate human iPSC-derived neurons, astrocytes, microglia, oligodendrocytes, endothelial cells, pericyte-like cells, or patient-specific and isogenic control lines. Cell identity, maturity, batch performance, and compatibility with the shared culture environment are assessed before the main study.

4. Which readouts are available for Brain-on-Chip studies?

   Readouts may include barrier permeability, junction imaging, transporter function, calcium imaging, multi-electrode-array activity, neurite and axon morphology, viability, apoptosis, mitochondrial or oxidative stress, glial activation, cytokines, disease-linked proteins, target engagement, compound recovery, and compartment-specific exposure.

5. Can Brain-on-Chip models evaluate blood-brain barrier penetration and downstream efficacy?

   Yes. A vascular channel can be dosed while concentrations, barrier integrity, and responses in the adjacent neural compartment are measured. The study can distinguish poor delivery, barrier toxicity, direct neural toxicity, and downstream pharmacological activity when the sampling and mass-balance plan is defined in advance.

6. How is model reproducibility assessed?

   Qualification can include leak and flow checks, tracer transport, cell identity, baseline viability, junction or lineage markers, spontaneous neural function, positive-control response, inter-chip variability, and predefined acceptance ranges. Replicates, plate layout, randomization, and analysis rules are specified before dosing.

7. What information is needed to start a custom Brain-on-Chip project?

   Helpful inputs include the research hypothesis, target or disease mechanism, preferred cell sources, required compartments, test-article properties, vehicle, intended exposure route, concentration range, desired endpoints, throughput, sample constraints, timeline, and the decision the data must support. If these are incomplete, a feasibility phase can define them.

References

1. Wevers, Nienke R., et al. "High-Throughput Compound Evaluation on 3D Networks of Neurons and Glia in a Microfluidic Platform." Scientific Reports, vol. 6, 2016, article 38856. https://doi.org/10.1038/srep38856
2. Koo, Youngmi, Brian T. Hawkins, and Yeoheung Yun. "Three-Dimensional (3D) Tetra-Culture Brain on Chip Platform for Organophosphate Toxicity Screening." Scientific Reports, vol. 8, 2018, article 2841. https://doi.org/10.1038/s41598-018-20876-2
3. Distributed under Open Access license CC BY 4.0, without modification.